Multiple Sclerosis Trial, Recruiting NCT06586177 Sponsor: Heinrich-Heine University, Duesseldorf Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT06586177
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with relapsing-remitting multiple sclerosis (RRMS) based on a specific set of diagnostic standards known as the 2017 revised McDonald criteria
  • People who are currently being treated with, or are starting or switching to, a type of MS medication that works by targeting B cells (a type of immune cell), used according to the approved prescribing guidelines
  • People whose level of physical disability, as measured by a standard MS scoring tool called the EDSS, falls between 0.0 and 7.0 (this scale measures how MS affects movement and daily function)

Who may not be able to join:

  • People who have previously been treated with any of the following medications or procedures: alemtuzumab, cladribine, cyclophosphamide, mitoxantrone, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow transplantation
  • People who have a medical, psychiatric, cognitive, or other condition that, in the trial doctor's judgement, would affect their ability to understand the study information and give informed consent
  • People who are receiving immune-suppressing medication for a condition other than MS, or who are on long-term steroid treatment
  • People who have a confirmed diagnosis of HIV (Human Immunodeficiency Virus) or Hepatitis C

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +492118117889

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Heinrich-Heine University, Duesseldorf
Registry
ClinicalTrials.gov
Start date
27 October 2021
Est. completion
31 December 2028

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Change from baseline in the peripheral immune cell profile; Change from baseline in protein profile of the peripheral blood; Change from baseline in TCR/BCR profile

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov